1 result for "Apexigen, Inc."
Add this URL to any RSS reader. Updated daily.
Anti-CD40 Antibodies and Methods of Use (Apexigen Patent Grant)
USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026. The patent covers high affinity anti-CD40 monoclonal antibodies and related compositions for therapeutic use in cancer and other diseases. Named inventors are Yongke Zhang, Guo-Liang Yu, and Weimin Zhu.
Routine
Notice
Intellectual Property
Get alerts for "Apexigen, Inc."
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
414
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
431
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
138
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "Apexigen, Inc."
We'll email you when new changes match "Apexigen, Inc.".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!